BioPhorum's Digital Technology Transfer Playbook lays out guiding principles for using digital tools, structured data, and digital product definitions to make technology transfer faster and more consistent.
Additional laboratory capacity supports development and scale-up of emerging oligonucleotide manufacturing technologies.
Investment to strengthen an integrated US pathway from amorphous solid dispersion via spray drying to tablet production at a single site, under one quality system.
Sterling Pharma Solutions has announced completion of an additional, large-scale GMP manufacturing suite at its dedicated bioconjugation facility in the UK, which will double capacity.
Bayer will invest $2.2 billion in a new pharma manufacturing site in New Albany, Ohio. The modular plant covers drug substance and product manufacturing, opening in phases from 2031.
As pharma outsourcing grows, CDMOs must balance speed and quality across intermediates, KSMs, RSMs and APIs, while process gaps and technology transfer challenge First-Time-Right scale-up.
The chairs of nine of Europe's largest pharmaceutical companies published a joint open letter warning that Europe's share of global pharmaceutical R&D has fallen.
Jean-Luc Herbeaux appointed Chief Executive Officer of CordenPharma, effective 1 October 2026. Michael Quirmbach to transition from President & CEO to Board Member and Senior Advisor.
China’s Biopharmaceutical and Medtech Sector in 2026
Pharma is turning to open-innovation platforms like Bayer Co.Lab to speed science to clinic. CHEManager’s Christene Smith talks to Ruth Shah about the model and its value for start-ups and pharma.
Since COVID, pharma manufacturers have shifted from lean, centralized supply chains toward regionalized hubs — balancing cost, flexibility, and geopolitical security to build resilience against future economic shocks.
In AI-driven biopharma R&D, success means spotting outside innovation. CSL's Nishtha Jain on building AI platforms for external innovation, keeping human judgment central, and evolving leadership amid AI and ethics.
Eli Lilly broke ground on a $6.5 billion Houston plant that will make Foundayo (orforglipron) and other medicines, creating over 600 jobs as part of its $50 billion push to reshore US drug manufacturing.
German CDMO Prange has sold all remaining shares in Adragos Pharma to FSN Capital.
What have been key moves—capacity additions and acquisitions by CDMOs of drug substances (small molecules and biologics) thus far in 2026? A roundup of key developments.
Milestone completes a $100 million investment cycle in New Jersey and supports Hovione’s long-term vision for a next-generation pharmaceutical development and manufacturing hub.
Explore how the flexible and efficient use of RABS and Isolators combined with operational expertise can address the challenges of aseptic processing.
PharmaBlock Sciences officially inaugurated its new OPC (Oligonucleotides, Peptides, and Conjugates) R&D Center in Nanjing, China.
Navigate complex CM decisions with the right excipients, practical testing access and process understanding.
Europe-wide 360° contract logistics for the pharmaceutical and healthcare industries are becoming even smoother—thanks to the new developments presented at CPHI in Milan.
CordenPharma is investing €80 million at its Caponago, Italy, site, adding a new facility and fill-finish lines to lift sterile injectable capacity to 500 million units/year, backed by shareholder Astorg.
The investment will reinforce the Bend site as a center of excellence for particle engineering and bioavailability enhancement and create a global manufacturing hub for commercial spray-drying.
Unveiled in April 2026, Brenntag's biopharma brand, Byphar, is aimed at companies in the biopharmaceutical industry. Joakim Rehné, President of Brenntag Pharma EMEA, explains the strategy behind the new brand.
Stefan Doboczky to take over operational leadership of the family-owned pharmaceutical technology and services group on April 1, 2027.
Northway Biotech is significantly expanding its development and manufacturing capacity with a new 3,500 sq. m facility featuring up to 20 independent cGMP manufacturing lines.
In 2026, Enamine celebrates 35 years — from a small grant-funded Kyiv lab to a global partner with 3,000+ people across six countries.
Samsung Biologics has published its formal offer prospectus to acquire PolyPeptide, deepening its push into peptide manufacturing as CDMOs race to expand capacity for GLP-1 and other peptide-based drugs.
New GMP (Good Manufacturing Practice) facility to meet increasing demand for lipid nanoparticle (LNP) development and clinical drug product manufacturing.
New APIs extend Wiley's gold-standard spectral data and analytical intelligence directly into lab, vendor, and platform workflows.
Expansion strengthens integrated manufacture of amorphous solid dispersions (ASDs) by spray drying and tableting at a single site, accelerating development and simplifying supply.
Piramal Pharma strengthens its biologics CDMO business, converting Yapan Bio from associate company to subsidiary and expanding vaccine and biologics manufacturing capabilities.
The first personalized mRNA cancer therapy to beat the standard of care is now headed for regulators.
A pharma project demonstrates how MTP can accelerate integration while reducing validation effort.
Eurofins CDMO Alphora has expanded its kilolab and high-potency active pharmaceutical ingredient (HPAPI) development and manufacturing capabilities in Ontario.
